I-MOVE: a network to measure vaccine effectiveness in Europe
This point is crucial to deploy an appropriate response, and in particular, to:
- decide on recommendations to be communicated for vaccine use
- yarget complementary or alternative measures (e.g. antivirals) for population subgroups in which the vaccine is less effective
- accurately estimate the impact of current vaccination strategies on the disease so as to support vaccination campaigns
- initiate further research on seasonal and pandemic vaccines (to improve composition, decide on the use of adjuvants or the need for booster doses),
- anticipate when the vaccine will be out of stock (especially during a pandemic)
In the Netherlands, data is being collected as part of the national influenza surveillance system by sentinel general practitioners participating in Nivel Primary Care Database in collaboration with RIVM.
The I-MOVE network was initiated with funding from Member States and the European Centre for Disease Prevention and Control (ECDC) and is being coordinated by Epiconcept (Paris). The last grant was reveived for the period 2019-2020.